Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Anal Canal Carcinoma
Anal Canal Squamous Cell Carcinoma
Stage IV Anal Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2014-12-11

Last Posted Date: 2025-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT02314169

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States

and more 53 locations

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Breast Carcinoma
Stage III Breast Cancer AJCC v7
Stage IIIA Breast Cancer AJCC v7
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Endoxifen Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Tamoxifen Citrate

First Posted Date: 2014-12-09

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 81

Registration Number: NCT02311933

Locations: 🇺🇸
Southern Cancer Center PC-Providence, Mobile, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 558 locations

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 1

Completed

Conditions: Gliosarcoma
Supratentorial Glioblastoma

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Other: Laboratory Biomarker Analysis
Drug: Temozolomide

First Posted Date: 2014-12-09

Last Posted Date: 2023-01-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT02311920

Locations: 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 8 locations

Comparing Pain in Patients Undergoing Percutaneous Versus Transjugular Techniques of Liver Biopsy

Completed

Conditions: Liver Disease

First Posted Date: 2014-12-08

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 32

Registration Number: NCT02311348

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

TODAY2 Phase 2 Follow-up

Completed

Conditions: Type 2 Diabetes

Interventions: Other: TODAY cohort

First Posted Date: 2014-12-08

Last Posted Date: 2021-08-05

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 517

Registration Number: NCT02310724

Locations: 🇺🇸
Yale University School of Medicine Department of Pediatrics, New Haven, Connecticut, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 12 locations

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Neoplasms
Cancer of Pancreas
Pancreatic Cancer
Pancreas Cancer
Cancer of the Pancreas

Interventions: Biological: Tremelimumab
Biological: Durvalumab
Radiation: Sterostatic body radiation therapy (SBRT)

First Posted Date: 2014-12-08

Last Posted Date: 2021-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT02311361

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Self-Affirmation, Emotion, and Alcohol Consumption

Completed

Conditions: Risk Reduction Behavior

First Posted Date: 2014-12-08

Last Posted Date: 2018-04-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 690

Registration Number: NCT02311400

Locations: 🇺🇸
GfK, Menlo Park, California, United States

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Phase 3

Active, not recruiting

Conditions: Metastatic Malignant Neoplasm in the Bone Marrow
Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Metastatic Ewing Sarcoma
Metastatic Malignant Neoplasm in the Bone
Metastatic Malignant Neoplasm in the Lung
Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Etoposide Phosphate
Radiation: External Beam Radiation Therapy
Drug: Ifosfamide
Biological: Ganitumab
Radiation: Stereotactic Radiosurgery
Procedure: Therapeutic Surgical Procedure
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2014-12-03

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 312

Registration Number: NCT02306161

Locations: 🇺🇸
Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States
🇺🇸
Ann M Wierman MD LTD, Las Vegas, Nevada, United States
🇺🇸
Flaget Memorial Hospital, Bardstown, Kentucky, United States

and more 311 locations

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Phase 1

Completed

Conditions: Recurrent Hodgkin Lymphoma
Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Metastatic Melanoma
Refractory Hodgkin Lymphoma
Stage III Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Unresectable Melanoma
Recurrent Non-Hodgkin Lymphoma
Refractory Osteosarcoma
Stage IIIA Cutaneous Melanoma AJCC v7

Interventions: Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Other: Pharmacological Study

First Posted Date: 2014-12-02

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 140

Registration Number: NCT02304458

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 22 locations

AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer
Colorectal Neoplasms
Colorectal Carcinoma

Interventions: Drug: AMP-224
Radiation: Stereotactic Body Radiation Therapy(SBRT)
Drug: Cyclophosphamide

First Posted Date: 2014-11-24

Last Posted Date: 2019-02-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT02298946

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy